Tumor-associated macrophages (TAMs) are M2 phenotype dominant and promote tumor growth and
metastasis. The new cancer treatment strategy includes TAM targeting and is aimed primarily at reprogramming
TAMs toward the M1 phenotype or reducing the number and activity of M2 macrophages. Several marine
invertebrate-derived drugs, combining efficacy and a low level of side effects, were approved for use in the cancer
therapy. The mechanisms of action of some of them include TAM targeting. The review includes data showing
immunomodulatory properties of these already approved anticancer drugs and drug candidates in clinical development
which additionally incorporate data from screening studies of new substances from marine invertebrates.
Based on screening data, the most promising marine compounds for cancer immunotherapy are supposed.
Keywords: Marine invertebrate-derived compounds, tumor-associated macrophages, macrophage reprogramming, cytokines, NO, anticancer
drugs, cancer immunotherapy.
Rights & PermissionsPrintExport